NCT03607565 A New Parameter Derived From DSA to Evaluate Cerebral Perfusion
| NCT ID | NCT03607565 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xi'an No.3 Hospital |
| Condition | Cerebral Ischemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 30,000 participants |
| Start Date | 2018-07-15 |
| Primary Completion | 2028-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30,000 participants in total. It began in 2018-07-15 with a primary completion date of 2028-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.
Eligibility Criteria
Inclusion Criteria: 1. Cerebral ischemia 2. patients undergone DSA Exclusion Criteria: 1.cerebral hemorrhage
Contact & Investigator
Nannan Han, doctor
STUDY DIRECTOR
department of neurology Xi'an No3 Hospital
Frequently Asked Questions
Who can join the NCT03607565 clinical trial?
This trial is open to participants of all sexes, studying Cerebral Ischemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03607565 currently recruiting?
Yes, NCT03607565 is actively recruiting participants. Contact the research team at chhty@sina.com for enrollment information.
Where is the NCT03607565 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT03607565 clinical trial?
NCT03607565 is sponsored by Xi'an No.3 Hospital. The principal investigator is Nannan Han, doctor at department of neurology Xi'an No3 Hospital. The trial plans to enroll 30,000 participants.